Arlington Partners LLC Gilead Sciences, Inc. Transaction History

Arlington Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 26, 2023	SELL	$76.01 - $86.7 $33,824 - $38,581	-445 Reduced 95.09%	23 $1,000
Q1 2023 Apr 26, 2023	BUY	$77.31 - $88.08 $36,181 - $41,221	468 New	468 $38,000
Q2 2022 Jul 25, 2022	BUY	$57.72 - $65.01 $26,262 - $29,579	455 Added 61.16%	1,199 $74,000
Q4 2021 Jan 18, 2022	SELL	$64.88 - $73.64 $118,470 - $134,466	-1,826 Reduced 71.05%	744 $54,000
Q3 2021 Oct 15, 2021	BUY	$67.69 - $73.03 $173,963 - $187,687	2,570 New	2,570 $180,000
Q2 2019 Jul 10, 2019	SELL	$61.87 - $69.38 $7,238 - $8,117	-117 Closed	0 $0
Q1 2019 Apr 05, 2019	BUY	$62.53 - $70.05 $7,316 - $8,195	117 New	117 $8,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Arlington Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Arlington Partners LLC with notifications on news.